Drug-induced Hypersensitivity Syndrome / Drug Reaction with Eosinophilia and Systemic Symptoms. Part I. Epidemiology, Pathogenesis, Clinicopathological Features, and Prognosis.
DHR
DRESS
DiHS
SCAR
delayed hypersensitivity reaction
drug rash
drug reaction
drug reaction with eosinophilia and systemic symptoms
drug-induced hypersensitivity syndrome
eosinophilia
exanthem
exanthematous drug eruption
hypersensitivity
maculopapular eruption
morbilliform eruption
severe cutaneous adverse drug reaction
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
27 Jul 2023
27 Jul 2023
Historique:
received:
28
09
2022
revised:
11
02
2023
accepted:
26
02
2023
medline:
30
7
2023
pubmed:
30
7
2023
entrez:
29
7
2023
Statut:
aheadofprint
Résumé
Drug-induced hypersensitivity syndrome (DiHS), also known as drug reaction with eosinophilia and systemic symptoms (DRESS), is a severe cutaneous adverse reaction (SCAR) characterized by an exanthem, fever, and hematologic and visceral organ involvement. Anticonvulsants, antibiotics, and allopurinol are the most common triggers. The pathogenesis involves a complex interplay between drugs, viruses, and the immune system primarily mediated by T-cells. DiHS/DRESS typically presents with a morbilliform eruption 2-6 weeks after drug exposure, and is associated with significant morbidity, mortality, and risk of relapse. Long-term sequelae primarily relate to organ dysfunction and autoimmune diseases. Part I of this continuing medical education activity on DiHS/DRESS provides an update on epidemiology, novel insights into pathogenesis, and a description of clinicopathological features and prognosis.
Identifiants
pubmed: 37516359
pii: S0190-9622(23)02402-7
doi: 10.1016/j.jaad.2023.02.072
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023. Published by Elsevier Inc.